title: Analysis of early phase [11C]BF-227 PET, and its application for anatomical standardization of late-phase images for 3D-SSP analysis.
abstract: OBJECTIVE
  To examine the usefulness of the early phase [(11)C]BF-227 positron emission tomography (PET) for (1) conferring additional diagnostic value by providing perfusion-like information and (2) obtaining the appropriate anatomical standardization (AS) using three-dimensional stereotactic surface projection (3D-SSP) method.
  
  
  METHODS
  This study included 20 mild cognitive impairment (MCI), 19 Alzheimer's disease (AD), and 17 normal cognitive (NC) subjects. Early- and late-phase BF-227 PET images were obtained 0-10 and 40-60 min after the injection, respectively. AS for late-phase BF-227 images were performed by 2 methods: (1) method A, for AS of late-phase BF-227 images using (8)F-fluorodeoxyglucose (FDG) images of the same subject and (2) method B, for AS of late-phase BF-227 images using early phase BF-227 images.
  
  
  RESULTS
  Method B was successfully used for AS in all cases. The Z score maps of 3D-SSP analyses of FDG PET and early phase BF-227 PET for AD and MCI groups showed a typical AD-like pattern. Regional analyses revealed that the early phase BF-227 PET showed significant differences between AD and NC, and MCI and NC.
  
  
  CONCLUSIONS
  The early phase BF-227 PET images showed significant abnormal findings for the AD and MCI groups. AS of late-phase BF-227 images using early phase BF-227 images were successful, and enabled appropriate 3D-SSP analyses.
authors.affiliation: Department of Diagnostic Radiology, Tohoku University, 1-1 Seiryomachi, Aobaku, Sendai, 980-8574, Japan, kaneta@rad.med.tohoku.ac.jp.
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Kaneta
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Okamura
authors.forename: Akira
authors.initials: A
authors.lastname: Arai
authors.forename: Kentaro
authors.initials: K
authors.lastname: Takanami
authors.forename: Katsutoshi
authors.initials: K
authors.lastname: Furukawa
authors.forename: Manabu
authors.initials: M
authors.lastname: Tashiro
authors.forename: Shozo
authors.initials: S
authors.lastname: Furumoto
authors.forename: Ren
authors.initials: R
authors.lastname: Iwata
authors.forename: Shoki
authors.initials: S
authors.lastname: Takahashi
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Arai
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Yanai
authors.forename: Yukitsuka
authors.initials: Y
authors.lastname: Kudo
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000000981:diagnostic imaging*; D001583:Benzoxazoles; D001921:Brain / Q000000981:diagnostic imaging; D002250:Carbon Radioisotopes; D060825:Cognitive Dysfunction / Q000000981:diagnostic imaging*; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D021621:Imaging, Three-Dimensional / Q000379:methods*; D008297:Male; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D013844:Thiazoles
chemical_list: C516779:2-(2-(2-dimethylaminothiazol-5-yl)ethenyl)-6-(2-(fluoro)ethoxy)benzoxazole; D001583:Benzoxazoles; D002250:Carbon Radioisotopes; D019275:Radiopharmaceuticals; D013844:Thiazoles; D019788:Fluorodeoxyglucose F18